Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Arseni, N
Right arrow Articles by Feuring-Buske, M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Arseni, N
Right arrow Articles by Feuring-Buske, M
Haematologica, Vol 90, Issue 11, 1577-1578
Copyright © 2005 by Ferrata Storti Foundation

Comparative Study

Effects of the protein tyrosine kinase inhibitor, SU5614, on leukemic and normal stem cells

N Arseni, F Ahmed, W Hiddemann, C Buske, and M Feuring-Buske

FLT3 activating mutations are the most frequent single genetic abnormality in patients with acute myeloid leukemia. Thus targeting the FLT3 activated kinase is a promising treatment approach. We wanted to test whether the protein tyrosine kinase inhibitor SU5614 selectively eliminates leukemic stem cells while sparing their normal counterparts.




HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2005 by the Ferrata Storti Foundation.